Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2018 pubmed 55 citations

Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response.

Thomi. Rahel R; Schlapbach. Christoph C; Yawalkar. Nikhil N; Simon. Dagmar D; Yerly. Daniel D; Hunger. Robert E RE

Key Findings

  • LL‑37 levels are elevated in hidradenitis suppurativa lesions, similar to psoriasis
  • Higher LL‑37 correlates with increased T‑cells, macrophages, neutrophils and cytokines like IFN‑γ, IL‑17, IL‑23, TNF‑α, IL‑32, IL‑1β
  • LL‑37 directly boosts proliferation of activated CD4⁺ T‑cells via calcium signaling, without needing antigen‑presenting cells

Practical Outcomes

  • For biohackers, this means that boosting LL‑37 (e.g., through supplements or topical use) could unintentionally amplify inflammatory immune responses, especially in skin conditions. If you have a history of inflammatory skin issues, be cautious with strategies that raise LL‑37. Targeting or moderating LL‑37 activity might become a therapeutic angle, but more research is needed before any protocol changes.

Summary

The study shows that the antimicrobial peptide LL‑37 is higher in the skin of people with hidradenitis suppurativa, a painful inflammatory condition, and that it’s linked to immune cells and inflammatory signals. It also finds LL‑37 can make certain T‑cells multiply by raising calcium inside the cells, independent of other immune helpers. This suggests LL‑37 plays a role in driving inflammation, not just fighting microbes.

Abstract

Hidradenitis suppurativa (HS) is an inflammatory skin disease with poorly understood immunopathogenic mechanisms. LL-37 is an antimicrobial peptide, which is transcribed from the CAMP (cathelicidin antimicrobial peptide) gene. Previous reports showed upregulated levels of CAMP and LL-37 in HS lesions, and therefore, the aim of this study was to compare levels of LL-37 in HS to other inflammatory skin diseases and to establish immunomodulatory functions of LL-37 in HS. We confirm an upregulation of the LL-37 peptide in lesional HS skin with comparable levels as in psoriasis patients and are able to positively correlate the presence of LL-37 in HS with the presence of T cells, macrophages, neutrophils, IFN-&#x3b3;, IL-17, IL-23, TNF-&#x3b1;, IL-32 and IL-1&#x3b2;. Mechanistically, LL-37 boosts the proliferation of unspecifically activated CD4<sup>+</sup> T cells via an increased calcium signalling independent of antigen-presenting cells. Targeting LL-37 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease, but it has to be kept in mind that LL-37 also has an antimicrobial function.

Study Information

Provider

pubmed

Year

2018

Date

2018-01-05T00:00:00.000Z

DOI

10.1111/exd.13482

Citations

55

References

43